文献速递临床生化临床免疫质量管理与危急值

新生儿物质暴露检测的生物学检测与结果解读

Biological Testing and Interpretation of Laboratory Results Associated with Detecting Newborns with Substance Exposure.
PubMed 文献 · Clin Chem · 2024-01-01

本文综述了检测孕产妇及新生儿物质暴露的常见样本类型(尿液、胎粪、脐带组织)和常用分析方法(免疫分析、质谱平台),强调检测目的、目标药物、具体方法及结果解读需结合临床背景,并指出所有检测方法均有局限性,需标准化。

要点

  • 检测新生儿物质暴露可用尿液、胎粪或脐带组织,各有优劣。
  • 免疫分析和质谱是常用检测平台,结果需在临床背景下解读。
  • 假阳性和假阴性结果可能发生,检测选择应基于目的和药物。

核心结论

  • 检测孕产妇和新生儿物质暴露的所有方法均有优势和局限性,需标准化以指导临床决策。
  • 若进行生物学采样,检测选项和结果必须在临床背景下审查,承认假阳性和假阴性可能发生。

研究设计与样本

  • 综述,回顾检测孕产妇和新生儿物质暴露的常见样本类型(尿液、胎粪、脐带组织)和常用分析方法(免疫分析、质谱平台)。

主要发现

  • 常用样本类型包括尿液、胎粪和脐带组织。
  • 常用分析方法包括免疫分析和质谱平台。
  • 检测利用需考虑检测目的、目标药物、具体检测方法及结果解读。
  • 存在意外结果的示例可用于指导解读和后续步骤。

临床怎么用

  • 检测选择应基于检测目的、目标药物和具体方法,结果需结合临床背景解读。
  • 遇到意外结果时应参考示例指导解读和下一步措施。

局限性

  • 所有检测方法均有局限性,假阳性和假阴性结果可能发生。
  • 缺乏标准化要求,包括检测时间、频率、样本类型、检测物质和操作方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Substance use during pregnancy is common, as is biological testing that is intended to help identify prenatal exposures. However, there is no standardized requirement for biological testing with either maternal or newborn specimens, nor is there standardization related to when testing occurs, how frequently testing occurs, what specimen(s) to test, what substances to test for, or how to perform testing. CONTENT: We review common specimen types tested to detect maternal and newborn substance exposure with a focus on urine, meconium, and umbilical cord tissue. We also review common analytical methods used to perform testing, including immunoassay, and mass spectrometry platforms. Considerations regarding the utilization of testing relative to the purpose of testing, the drug analyte(s) of interest, the specific testing employed, and the interpretation of results are emphasized to help guide decisions about clinical utilization of testing. We also highlight specific examples of unexpected results that can be used to guide interpretation and appropriate next steps. SUMMARY: There are strengths and limitations associated with all approaches to detecting substance exposure in pregnant persons as well as biological testing to evaluate a newborn with possible substance exposure. Standardization is needed to better inform decisions surrounding evaluation of substance exposures in pregnant people and newborns. If biological sampling is pursued, testing options and results must be reviewed in clinical context, acknowledging that false-positive and -negative results can and do occur.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. McMillin GA, Morad AW, Boyd JM, et al. Biological Testing and Interpretation of Laboratory Results Associated with Detecting Newborns with Substance Exposure. Clin Chem. 2024. PMID: 38549034. doi:10.1093/clinchem/hvae018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。